Initial studies of second generation ALK inhibitors, such as ceretinib and alectinib, have shown increased CNS penetration, decreased radiological burden of metastases and LMD, and improvement in symptoms [126–131]. This evidence concerns the gene ALK and Langer mesomelic dysplasia.